EGFR T790M
A change that often appears as a resistance mechanism after early-generation EGFR inhibitors.
Parent marker: EGFR
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Clinical meaning
T790M was discussed as the reason earlier generation therapies stopped working. Third-generation inhibitors are designed to remain active at these changes.
How this finding appears in a report
Examination is often performed of new tissue or blood samples after progression.
When therapy stops working
After third-generation therapy, C797S alterations and non-EGFR mechanisms became part of re-examination.
What needs verification
- Complete variant name as written in the laboratory report.
- Examination methods and types of samples used.
- Examination dates were compared with ongoing therapy.
Marker context: EGFR
A common EGFR mutation (exon 19 deletion, L858R) alters the way systemic therapy is selected in non-small-cell lung cancer. Other groups of mutations, including exon 20 insertions, are generally considered distinct and are often directed to other pathways, including clinical trials.
A negative result does not always mean absent
Summary
- Gen
- EGFR
- Variant
- EGFR T790M
- Alteration type
- Mutation
- Discussed in
- Lung Cancer
- Updated
- 2026-09-10
Other names in reports
T790M
Drugs discussed
Treatment categories
Related guides
Sources
- NCI Dictionary of Cancer Terms(lembaga)
- ClinicalTrials.gov(registry)
Clinical trials
Studies mentioning marker EGFR
Filtered from public study descriptions. Access status and site readiness remain unverified.
NCT03191149Phase 2Targeted therapy
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Lung Cancer | biomarker: EGFR | Targeted therapy
United States347 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker EGFR, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT03191149Not verified
NCT07874490Phase 2Targeted therapy
Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLC
Lung Cancer | biomarker: EGFR | Targeted therapy
United States1 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker EGFR, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07874490Not verified
NCT04181060Phase 3Targeted therapy
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Lung Cancer | biomarker: EGFR | Targeted therapy
United States603 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker EGFR, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT04181060Not verified
NCT07185997Phase 3Targeted therapy
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Lung Cancer | biomarker: EGFR | Targeted therapy
United States, Australia, Canada +14139 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker EGFR, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07185997Not verified
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- EGFR
Biomarker
Reason: Related through a biomarker
- Lung Cancer
Cancer type
Reason: Related to this page
- Osimertinib
Drug
Reason: Related to this page
- Targeted therapy
Treatment category
Reason: Related to this page
To check
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.